**3. Conclusions**

Oral cancer is primarily a surgically managed disease. However, treatment needs to be personalized based on subsite, stage and biology of tumor, patient health profile and the infrastructure and expertise available. Appropriate management of cervical nodal metastases has a direct bearing on prognosis. Reconstructive options must be tailored to suit patient needs in order to regain as much as possible form and function. Adjuvant treatment adherence and regular follow-up in the surveillance period should be adhered to.

## **4. Future prospects**

PDL1 (programmed death ligand) antagonists are gaining promise as an alternative for recurrent and metastatic head and neck cancers [23]. Targeting the m TOR pathway for exploring resistance to Cetuximab is established [24]. Research and interest in Immunotherapy is also increasing however, it is still only in an experimental phase.
